(Press-News.org) Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health (NIH) and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology (JASN).
Diabetic nephropathy remains the leading cause of end-stage kidney disease (ESKD) in the United States. It is a common complication of diabetes, in which kidney cells are damaged as a result of high blood sugar levels.
"The dramatic finding of this exploratory study is that an appropriate dose of pirfenidone not only halted decline but actually improved kidney function in these patients," said Kumar Sharma, MD, FAHA, professor of medicine in the UCSD division of nephrology and director of the Center for Renal Translational Medicine, who headed the study.
The principal process underlying the progression of chronic kidney disease to ESKD – where dialysis is required to keep a patient alive – is called renal (kidney) fibrosis. The fibrosis, or scarring, damages tiny blood vessels in the glomerulus, structures that filter and remove waste from the blood, and in between tubular cells.
Transforming growth factor beta (TGF-β) is a protein that controls many cellular functions, including extracellular matrix accumulation. TGF-β is stimulated in the diabetic kidney due to uncontrolled blood sugar and elevated blood pressure and can promote renal fibrosis.
"To date, therapies for diabetic nephropathy have been limited to drugs that improve blood pressure or control blood sugar levels," said Sharma. Instead, pirfenidone seems to work by blocking TGF-β; in effect, shutting down the growth factors that cause renal fibrosis.
The UCSD researchers previously observed a very dramatic benefit in a mouse model of diabetic kidney disease, in a study published in JASN two years ago. The animal studies showed improvement in matrix accumulation at gene and protein levels with just four weeks of treatment.
The new randomized, double-blind study of 77 patients with diabetic nephropathy was conducted at Thomas Jefferson Hospital in Philadelphia, the Mayo Clinic in Rochester and the NIH, and comprised three study groups: one group received a high dose of pirfenidone (2400 mg); one group received a low dose of pirfenidone (1200 mg); and a control group.
The UCSD researchers analyzed the rate of decline in kidney function in the three groups by measuring the estimated glomerular filtration rate, or eGFR. They found a significant improvement in the low-dose group over the course of the one-year study. There was no seeming benefit to those patients who received the high dose, suggesting that higher doses may not be tolerable in the diabetic population with moderate to advanced chronic kidney disease.
Sharma states the next step is to perform a larger clinical study and to identify personalized biomarkers, to determine which patients are most apt to show improvement on the drug. "This drug might also be useful in treating other types of fibrotic disease," he added.
"We have previously found that pirfenidone slows progressive loss of kidney function in another chronic kidney disease, called focal segmental glomerulosclerosis," said Jeffrey B. Kopp, MD, NIH/NIDDK intramural researcher and Capt., USPHS. "By extending these findings to the most common chronic kidney disease – diabetic kidney disease – the present study suggests that pirfenidone may have broad utility to help patients maintain kidney function longer."
###
Additional contributors to the study included Joachim H. Ix, Anna V. Mathew, Shoba Sharma, Michael Donohue, Satish RamachandraRao, and Ronghui Xu, of UCSD; Monique Cho and Jeffrey B. Kopp, National Institute of Diabetes and Digestive and Kidney Diseases, NIH; Axel Pflueger and Fernando C. Fervenza, Mayo Clinic, Rochester, Minnesota; Tracy A. McGowan, formerly at Thomas Jefferson University and now at Johnson and Johnson; Stephen R. Dunn, Kimmel Cancer Center and Thomas Jefferson University; Bonita Falkner and Barbara Francos, Thomas Jefferson University.
Funding for this study was provided in part by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, and the Juvenile Diabetes Research Foundation.
Drug effective in treating kidney disease in diabetic patients
2011-04-24
ELSE PRESS RELEASES FROM THIS DATE:
LateRooms.com - Open de Espana Returns to Barcelona
2011-04-24
It has been more than a decade since Barcelona's Real Club de Golf El Prat hosted the Open de Espana.
The competition will make its triumphant return to the Catalan course on May 5th, with many of the top golfing professionals from the European Tour expected to star.
As well as the chance to boost their rankings, players are also competing for a prize pot of EUR2 million (GBP1.7 million).
The Open de Espana has previously been won by illustrious names such as Sergio Garcia, Padraig Harrington, Colin Montgomerie and Seve Ballesteros.
It is one of the oldest tournaments ...
Subset of self-destructive immune cells may selectively drive diabetes
2011-04-24
New research identifies a distinctive population of immune cells that may play a key role in the pathogenesis of diabetes. The research, published by Cell Press and available online in the April 21st issue of Immunity, sheds new light on the pathogenesis of diabetes and may lead to the development of new more selective therapeutic strategies for diabetes and other autoimmune diseases of the accessory organs of the digestive system.
Type 1 diabetes (T1D) is a chronic autoimmune disease that develops when the immune system destroys insulin-producing cells in the pancreas. ...
Kidney disease coupled with heart disease common problem in elderly
2011-04-24
Patients on peritoneal dialysis (PD) typically have a higher early survival rate than patients on hemodialysis (HD). New data suggest that this difference may be explained by a higher risk of early deaths among patients undergoing HD with central venous catheters, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
In a study that included more than 38,500 Canadian patients starting dialysis between 2001 and 2008, 63 percent started hemodialysis using a central catheter placed into one of the large veins. Seventeen ...
LateRooms.com - See A Hard Merciless Light in Madrid
2011-04-24
Madrid's Museo Nacional de Arte Reina Sofia is showing a collection of pictures from the worker-photography movement between 1926 and 1939.
A Hard Merciless Light will be on display until August 22nd 2011, displaying some fascinating examples of images used during that era in the press.
The installation explores how the partnership of photography and the leftist worker movement became intertwined and spread from humble beginnings in the Soviet Union to several other countries including the US and Spain.
In a statement, the organisers remarked: "The exhibition ...
Say hello to cheaper hydrogen fuel cells
2011-04-24
LOS ALAMOS, New Mexico, April 22, 2011—Los Alamos National Laboratory scientists have developed a way to avoid the use of expensive platinum in hydrogen fuel cells, the environmentally friendly devices that might replace current power sources in everything from personal data devices to automobiles.
In a paper published today in Science, Los Alamos researchers Gang Wu, Christina Johnston, and Piotr Zelenay, joined by researcher Karren More of Oak Ridge National Laboratory, describe the use of a platinum-free catalyst in the cathode of a hydrogen fuel cell. Eliminating ...
A new ending to an old 'tail'
2011-04-24
LA JOLLA, CA—In stark contrast to normal cells, which only divide a finite number of times before they enter into a permanent state of growth arrest or simply die, cancer cells never cease to proliferate. Now, scientists at the Salk Institute for Biological Studies have uncovered an important clue to one of the mechanisms underlying cancer cell immortality.
Their findings, published in the April 22, 2011 issue of Molecular Cell, reveal an unanticipated structure at chromosome ends, which could be a key ingredient in the biological "elixir of life," potentially making ...
Hotels-Paris.co.uk - Rembrandt and the Face of Jesus Unveiled in Paris
2011-04-24
A major new exhibition called Rembrandt and the Face of Jesus opened at Paris's Louvre art space on Thursday (April 21st).
The installation will be on show until July 18th 2011 and sees world-famous masterpiece The Pilgrims at Emmaus take centre stage.
Rembrandt Harmenszoon van Rijn - best known by his first name - painted it in the 17th century.
The picture will form the centrepiece for an installation that explores the way Jesus was represented in his art, as well as in the paintings of his students.
Tickets for the exhibition cost EUR11 (GBP9.75), or visitors ...
Bacteria interrupted: Disabling coordinated behavior and virulence gene expression
2011-04-24
New research reveals a strategy for disrupting the ability of bacteria to communicate and coordinate the expression of virulence factors. The study, published by Cell Press in the April 22nd issue of the journal Molecular Cell, may lead to the development of new antibacterial therapeutics.
Bacteria use a process called "quorum sensing" to synchronize group behaviors that promote pathogenesis. During the process of quorum sensing, bacteria communicate with one another via chemical signals called autoinducers. As the population increases, so do autoinducer concentrations. ...
LateRooms.com - Liverpool Showcases Like You've Never Been Away
2011-04-24
Like You've Never Been Away is a heart-warming project for which a photographer has tracked down the people who appeared in his photographs of Granby and Everton in 1975.
Paul Trevor was sent to the areas to record inner city deprivation and produced a collection of images showing the defiant nature with which the communities faced their problems.
In a statement, he described how he found everyone to be full of humour and energy at the time and decided to revisit the project and update the public on what the participants had done with themselves after he left.
Mr ...
Columbia engineering study links ozone hole to climate change all the way to the equator
2011-04-24
In a study to be published in the April 21st issue of Science magazine, researchers at Columbia University's School of Engineering and Applied Science report their findings that the ozone hole, which is located over the South Pole, has affected the entire circulation of the Southern Hemisphere all the way to the equator. While previous work has shown that the ozone hole is changing the atmospheric flow in the high latitudes, the Columbia Engineering paper, "Impact of Polar Ozone Depletion on Subtropical Precipitation," demonstrates that the ozone hole is able to influence ...